{
    "success": true,
    "data": {
        "type": "ETF",
        "ucits": false,
        "leverage": true,
        "derivatives": true,
        "swaps": true,
        "inverse": false,
        "replication_method": "synthetic",
        "complex_factors": [
            "Leverage (3x daily)",
            "Compounding Effect",
            "Synthetic Replication (implied by 'Index which provides exposure to 3 times the daily performance')",
            "High Risk Classification (Class 7/7)",
            "No Capital Protection",
            "Intended for Sophisticated Investors",
            "Potential loss of entire investment",
            "No Investor Compensation Scheme"
        ],
        "classification": "complex",
        "supporting_data": "The product is classified as 'complex' primarily due to its leveraged nature (3x daily performance) and the inherent 'Compounding Effect' which can lead to returns significantly different from the underlying asset's performance over longer periods. The use of synthetic replication (implied by tracking an index for leveraged exposure) introduces complexity related to derivatives and counterparty risk. Furthermore, the 'Risk indicator 7/7' and the explicit mention that it is 'not simple and may be difficult to understand', intended for 'sophisticated investors', and having 'no capital protection' all point towards a complex classification. The absence of UCITS compliance further supports this, as UCITS are generally presumed non-complex unless specific features dictate otherwise. According to MiFID II, instruments with leveraged and synthetic replication structures typically require an appropriateness test due to their inherent complexity and the difficulty retail investors with basic knowledge would have in understanding the risks involved, especially concerning counterparty risk and the compounding effect. As per ESMA guidelines, financial instruments that are leveraged or use derivatives centrally to their strategy are generally considered complex."
    }
}